血液肿瘤科始建于20世纪80年代初，由前辈谢竞雄教授以及蒋慧教授领衔创建并开拓发展。重点关注儿童恶性血液病/肿瘤和难治性血液病的临床诊治和研究，获得具有专业特色的科室，并率先在国际上应用全反射维甲酸治疗儿童急性早幼粒性白血病获得成功，推动了国际性一系列的临床研究。2016年8月蒋慧教授带领团队开展外周造血干细胞移植，重点开展单倍体半相合造血干细胞移植(HID)。目前完成35例，HID80%以上，植入率95%，无病生存率（DFS）90.0%，移植相关死亡率8.5%，III-IV度aGVHD发生率8.5%，cGVHD发生率10.0%。病种包括难治复发白血病、重型再生障碍性贫血、遗传性溶血性贫血、高IgM综合征、先天性骨髓衰竭性疾病、联合免疫缺陷病等。总体疗效达到国内外先进水平，改变了儿童移植供体不足的困难。于2018年5月开始应用CAR-T细胞免疫技术治疗难治反复复发急性淋巴细胞性白血病，迄今已有5例，CAR-T治疗后成功率100%，严重细胞反应80%，最长无病生存（DFS）10个月，平均DFS 9.75个月。科室立足打造严谨、务实、探索、开拓和创新精神，为难治恶性血液病患者提供最好的医疗和服务。

Department of Hematology and Oncology

The Department of Hematology and Oncology was established in the early 1980s and was led by Professor Xie Jingxiong and Professor Jiang Hui. Focusing on the clinical diagnosis, treatment and research of children's malignant hematological diseases/tumors and refractory hematological diseases，department have formed it’s own characteristics.We are the first to use retinoic acid in the treatment of childhood acute promyelocytic leukemia in the world, that has promoted a series of international clinical studies. In August 2016, the team led by Professor Hui Jiang carry out peripheral hematopoietic stem cell transplantation, focusing on haploid hematopoietic stem cell transplantation (HID). To date, 35 cases have been completed, and more than 80% of them were with HID. The implantation rate of haplo-HSCT was 95%, the disease-free survival rate (DFS) was 90%. The transplant-related mortality rate was 8.5%. The incidence of III-IV degree of aGVHD was 8.5% and cGVHD was 10%. The diseases include recurrent refractory leukemia, severe aplastic anemia, hereditary hemolytic anemia, hyper IgM syndrome, congenital bone marrow failure, severe combined immunodeficiency disease, etc. The overall curative effect has reached the advanced level at home and abroad, which has changed the difficulty of insufficient donor for child patients. CAR-T cell immunoassay has been used to treat refractory recurrent acute lymphoblastic leukemia since May 2018. So far, there have been 5 cases, with 100% success rate after CAR-T treatment, 80% severe cell reaction, 10 months of longest disease-free survival (DFS) and 9.75 months of average DFS. We are based on the spirit of rigorousness, pragmatism, exploration, pioneering and innovation to provide the best medical treatment and services for patients with refractory malignant hematological diseases.